Quintiles Extends Phase I Capacity and Capabilities
Quintiles announced the opening of its expanded research facility in London, UK, designed to increase Phase I capacity and extend its ability to drive progress in translational medicine. The facility is housed on the 14th floor of Guy's Hospital, adjacent to a Biomedical Research Centre (BRC).
With capacity for 35 patients and healthy volunteers, the extension brings the total number of Phase I beds in London to 105 and globally to 385. This is expected to increase further in late 2010, with the opening of a Phase I unit in Hyderabad, India, initially with 50 beds, and with capacity for expansion to 100.
“Declining productivity in research and development means that the biopharmaceutical industry is under intense pressure to increase efficiency and overcome complexity,” explains Eddie Caffrey, Senior Vice President, Global Phase I at Quintiles.
“Effective early-stage development can have significant impact on speed and cost of the overall development process. Our customers need a holistic solution that combines fast and cost-efficient regulatory studies with advanced scientific expertise and techniques such as modeling and simulation, biomarkers and microdosing for more complex studies."
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials
September 10th 2024The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.
